Don’t let complex sequence listings delay your patents. Our expert team delivers perfectly formatted, PTO-compliant ST.26 listings – new or converted from ST.25- that pass validation first time sequence listing services. Trusted by leading patent attorneys and IP departments, we process thousands weekly, ensuring reliable, accurate support for your valuable innovations.
Patent applications disclosing DNA, RNA, or peptide sequences – such as those involving biomarkers, antibodies, or oligonucleotides – must include a separate sequence listing document. This requirement ensures clear, standardized disclosure of sequences, aiding patent offices in examination and public access. Listings must follow formats like WIPO ST.26 or ST.25, and apply to nucleotide sequences with ten or more bases and amino acid sequences with four or more residues.
Biotech innovators
Researchers
Patent applicants
ST.25 & ST.26 users
Institutions
Biotech innovators
Researchers
Patent applicants
ST.25 & ST.26 users
Institutions
Our budget-friendly pricing models adapt to your specific needs, offering exceptional value without compromising quality.
We provide free iterations until you're 100% satisfied with the results. Your complete confidence in our work is our ultimate goal.
We've built our reputation on providing QUICK, ECONOMIC, and ACCURATE sequence listing services. Patent law firms and corporations trust us completely for their critical IP needs, knowing we deliver flawless results every time.
No biological sequence challenge is beyond our capabilities. Our expert team confidently handles the most intricate sequence structures while ensuring 100% compliance with all patent office regulations.
Our dedicated team of 30+ biotechnology specialists prepares thousands of SEQUENCE LISTINGS DAILY. This unparalleled volume gives us unique insights into potential issues and optimal formatting strategies across diverse biological patents.
We excel at processing massive sequence listings, including projects with up to 2.5 million sequences. Our robust systems and specialized workflows ensure accuracy even at extraordinary scale.
We prioritize error-free, PTO-compliant listings above all else. In the rare case of errors, we address these cases with absolute priority at no additional cost—your success is our commitment.
Experience our effortless ordering process and expedited delivery within 4-5 business days, with even faster options available for urgent needs.
Document Analysis
We carefully review your patent documents to identify all biological sequences
Sequence Extraction
All relevant sequences are extracted and properly formatted
Listing Creation
Compliant sequence listings are generated according to required standards
Validation & Quality Check
Multi-level verification ensures complete accuracy
Delivery
Final listings provided in required formats with documentation
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
A sequence listing contains nucleotide and/or amino acid sequences disclosed in a patent application and forms part of the description. It includes descriptive information about each sequence, known as annotations, and conforms to the requirements of the relevant WIPO standard (ST.25 or ST.26). It allows the sequence data of an invention to be searchable within an IP office and in publicly available databases (e.g., INSDC databases).
They ensure uniformity in disclosure of biological sequences across patent applications worldwide, facilitating examination and enabling efficient electronic data exchange between patent offices.
A sequence listing is required when your patent application discloses one or more nucleotide or amino acid sequences that fall within the definition of sequence disclosure under applicable rules.
ST.26 is the current global standard for sequence listings in XML format, replacing the older ST.25 standard. It became mandatory for all international patent applications filed on or after July 1, 2022.
ST.26 differs from ST.25 by using XML instead of plain text, requiring the inclusion of D-amino acids, branched sequence portions, and nucleotide analogs. It also allows more detailed annotations with feature keys and qualifiers, and prohibits sequences shorter than 10 nucleotides or 4 amino acids, which ST.25 permits.
Yes, ST.26 is mandatory for all international patent applications (PCT) filed on or after July 1, 2022, and for many national/regional applications depending on local implementation.
All disclosed sequences with 10+ nucleotides or 4+ amino acids must be included, whether in claims, description, drawings, or sequence listing.
Yes, modified nucleotides and amino acids must be included and appropriately annotated according to ST.26 rules.
Sequences shorter than 10 nucleotides or 4 amino acids should not be included in ST.26 sequence listings unless specifically required by local rules.
WIPO’s free WIPO Sequence tool is the recommended software for preparing and validating ST.26-compliant sequence listings.
WIPO Sequence can be downloaded from the WIPO website at www.wipo.int/standards/en/sequence.
Yes, WIPO Sequence includes a validation function that checks your sequence listing for compliance with ST.26 requirements.
ST.26 sequence listings must be submitted in XML (XML = eXtensible Markup Language) format with a .xml file extension.
Size limits vary by patent office. For large files, consult your target patent office for submission options.
Yes, but late submission may require additional fees and cannot add new matter to the application.
Branched sequences should be represented as multiple linear sequences, with each branch represented separately.
D-amino acids are represented using the same one-letter codes as L-amino acids but must include a “feature” annotation specifying “D-configuration.”
Use the most restrictive symbol possible (e.g., “N” for nucleotides, “X” for amino acids) and include appropriate feature annotations.
ST.26 sequence listings must use UTF-8 encoding.
Follow your patent office requirements. For PCT applications, use the format “[application_number]_sequence_listing.xml”.
Free text in qualifier values should be in English or include both original language and English translation.
Common errors include inconsistent annotations, incorrect feature locations, missing mandatory qualifiers, and improper formatting of modified residues.
Sequence listing errors may result in requests for correction, potential filing date issues, or prosecution delays.
Correction protocols vary by jurisdiction. Generally, you must submit a replacement listing with a statement that the correction introduces no new matter.
Effectual Services is an award-winning Intellectual Property (IP) management advisory & Consulting firm.